Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Pediatric Recurrent DIPG
NCT00600054Phase 2Completed
- Sponsor
- YM BioSciences
- Start
- Oct 2007
- Primary completion
- Mar 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of nimotuzumab in diffuse intrinsic pontine glioma (DIPG), sponsored by YM BioSciences. Started Oct 2007; status: completed.
02
Drugs
nimotuzumab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT00600054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600054.